News|Articles|December 1, 2004

New molecular entities: erlotinib, solifenacin, natalizumab

New molecular entities: erlotinib, solifenacin, natalizumab


Related to this article

Stafeeva-stock@adobe.com
Pharmacy benefit managers are moving beyond formulary access to provide support programs for women's health. Here's how three PBMs — Judi Health, LucyRx and RxPreferred — are putting that strategy into practice.